Massive chart review aims to unravel cachexia in lung and GI cancers
NCT ID NCT03606317
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at the medical records of 20,000 patients with lung or gastrointestinal cancer who also have cachexia (severe weight loss and muscle wasting). The goal is to learn how cachexia is currently managed and what factors affect patient outcomes. No treatments or tests are given; researchers simply analyze existing data from two hospitals.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better understand how cachexia progresses and how it is currently managed, pointing toward improved care guidelines.
- What could go wrong
- This is a retrospective chart review, not a treatment trial. It cannot prove what works best, only describe past practices. Results may not apply to other hospitals or patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 20,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2013
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjects medical charts will be identified in the medical record data warehouses with diagnosis of lung or gastrointestinal cancer during the above time frame. Data from charts will be entered into a password protected excel spreadsheet. The charts will be identified by name, medical record number, and date of birth. These are all patients treated by all hospitals and clinics affiliated with the Parkland and UT Southwestern Health Systems. At the time of study, many of the patients will have expired but some will be alive and in the regional North Texas area. Thus, given the fact the majority of patients will have expired at the time of this study and the minimal risk nature of this retrospective chart review, we could not reasonably conduct this research with a full waiver of consent.
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Medical charts representing patients with a diagnosis of lung or gastrointestinal cancer with a tissue diagnosis from 1/1/2005 and onward treated at UT Southwestern or Parkland. Exclusion Criteria: There will be no absolute exclusion criteria as long as the inclusion criteria have been met.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cachexia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Surgeons could freeze lung tumors from miles away using 5G robots
- Can AI make lung cancer scans easier to read?
- Two-Drug combo targets Treatment-Resistant lung cancer
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- App aims to catch a hidden radiotherapy side effect
- Which nerve block wins for lung surgery pain?